Granocyte 34 is a brand name for a medication that contains the active ingredient lenograstim, which is a type of granulocyte colony-stimulating factor (G-CSF). It is a recombinant form of human G-CSF and is produced using biotechnology. Granocyte 34 is primarily used to stimulate the production of white blood cells (granulocytes) in patients who have undergone chemotherapy, bone marrow transplantation, or are suffering from severe chronic neutropenia. The increase in white blood cells helps to reduce the risk of infection in these patients. It is administered via subcutaneous injection or intravenous infusion, depending on the specific needs and condition of the patient. Granocyte 34 plays a crucial role in managing neutropenia and supporting the immune system during critical treatments, thereby improving patient outcomes and quality of life.